Daniel DiLorenzo, MD, PhD, MBA, is a renowned healthcare entrepreneur and inventor, specializing in functional neurosurgery, intellectual property, and management of technology. He has an extensive background in neuroscience and implanted medical devices as a PhD holder from MIT. He also holds an MBA in Management of Technology, which he earned from MIT Sloan School of Management. As an experienced registered patent agent, he is proficient in drafting and prosecuting complex interdisciplinary medical device patents.

DiLorenzo is the founder, president and CEO of Dilorenzo Biomedical, a leading company that specializes in the identification, validation, and commercialization of new opportunities within the healthcare and medical technology industries. He was also the founding CEO, Chairman, and CTO of NeuroVista Corporation, where he invented technology and secured patents, recruited a team, crafted the initial business, clinical strategies, and raised venture financing. NeuroVista demonstrated statistically and clinically significant advance warning of seizures in a First In Man (FIM) study in 2013.

Having served as an assistant professor of neurosurgery at Loma Linda University, Daniel DiLorenzo has an extensive experience in managing patients and surgically implanting neuromodulation technologies. Additionally, DiLorenzo has served on various advisory boards and held different academic positions, including interim chairman and professor, Department of Neurosurgery at the University of Kansas School of Medicine, where he was also responsible for developing an interdisciplinary neuromodulation program.

DiLorenzo has contributed significantly to the world of neuroscience; he is the editor of the textbook, “Neuroengineering,” and has authored many articles in reputable journals. He has also been invited to present at various conferences, including Neurotech Leaders Forum, Cleveland Clinic Innovation Summit, MIT NeuroVentures, and North American Neuromodulation Society.